<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199274</url>
  </required_header>
  <id_info>
    <org_study_id>17F.222</org_study_id>
    <nct_id>NCT03199274</nct_id>
  </id_info>
  <brief_title>Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer</brief_title>
  <official_title>Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well perflutren protein-type A microspheres and&#xD;
      contrast-enhanced ultrasound work in improving response to radioembolization therapy in&#xD;
      patients with liver cancer. Ultrasound contrast agents, such as perflutren protein-type A&#xD;
      microspheres, use gas microbubbles to improve image quality. Using contrast-enhanced&#xD;
      ultrasound imaging will &quot;pop&quot; these microbubbles and cause tumors to become more sensitive to&#xD;
      radiation therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Characterize the ability of localized ultrasound contrast agent destruction to improve&#xD;
      hepatocellular carcinoma (HCC) response to yttrium Y-90 (Y90) radioembolization.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Determine if contrast-enhanced ultrasound estimated tumor perfusion can reliably predict&#xD;
      HCC response to radioembolization 1-14 days post treatment.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I: Patients receive perflutren protein-type A microspheres intravenously (IV) over 10&#xD;
      minutes and undergo contrast-enhanced ultrasound (CEUS) over 60 minutes at 1-6 hours and at&#xD;
      approximately 7 and 14 days after yttrium Y-90 radioembolization.&#xD;
&#xD;
      GROUP II: Patients undergo standard of care yttrium Y-90 radioembolization.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 month and at 3-4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response to yttrium Y-90 radioembolization</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Measured using the modified Response Evaluation Criteria in Solid Tumors. Will be tested with a non-parametric Mann- Whitney U-test of the difference in response distributions between control (radioembolization alone) and experimental group (ultrasound-triggered microbubble destruction [UTMD] + radioembolization). The outcome variable in this analysis, the modified Response Evaluation Criteria in Solid Tumors (mRECIST) score, is treated as an ordinal variable in this analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Perfusion will be characterized in terms of contrast replenishment time intensity curves fit with a 2-parameter exponential recovery curve. The relationship between the normalized perfusion values from this image processing and the patients' subsequent mRECIST scores in the UTMD + radioembolization group will be evaluated with Spearman's rank order correlation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group I (perflutren protein-type A microspheres, CEUS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 1-6 hours and at approximately 7 and 14 days after yttrium Y-90 radioembolization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard of care yttrium Y-90 radioembolization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Yttrium-90 Microsphere Radioembolization</intervention_name>
    <description>Undergo standard of care Y-90 radioembolization</description>
    <arm_group_label>Group I (perflutren protein-type A microspheres, CEUS)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <other_name>Yttrium Y 90 Microsphere Therapy</other_name>
    <other_name>Yttrium-90 Radioembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perflutren Protein-Type A Microspheres</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Group I (perflutren protein-type A microspheres, CEUS)</arm_group_label>
    <other_name>Optison</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dynamic Contrast-Enhanced Ultrasound Imaging</intervention_name>
    <description>Undergo CEUS</description>
    <arm_group_label>Group I (perflutren protein-type A microspheres, CEUS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be scheduled for sub-lobar radioembolization therapy of a previously untreated HCC&#xD;
             mass &lt; 6 cm visible on grayscale ultrasound&#xD;
&#xD;
          -  Be medically stable&#xD;
&#xD;
          -  If a female of child-bearing age, have a negative pregnancy test prior to each&#xD;
             ultrasound exam&#xD;
&#xD;
          -  Have signed informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or nursing&#xD;
&#xD;
          -  Patients who are medically unstable, patients who are seriously or terminally ill, and&#xD;
             patients whose clinical course is unpredictable; for example:&#xD;
&#xD;
               -  Patients on life support or in a critical care unit&#xD;
&#xD;
               -  Patients with unstable occlusive disease (e.g., crescendo angina)&#xD;
&#xD;
               -  Patients with clinically unstable cardiac arrhythmias, such as recurrent&#xD;
                  ventricular tachycardia&#xD;
&#xD;
               -  Patients with uncontrolled congestive heart failure (New York heart Association&#xD;
                  [NYHA] class IV)&#xD;
&#xD;
          -  Patients with recent cerebral hemorrhage&#xD;
&#xD;
          -  Patients with known sensitivities to albumin, blood, or blood products&#xD;
&#xD;
          -  Patients with known hypersensitivity to perflutren&#xD;
&#xD;
          -  Patients with known cardiac shunts&#xD;
&#xD;
          -  Patients with known congenital heart defects&#xD;
&#xD;
          -  Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary&#xD;
             embolism&#xD;
&#xD;
          -  Patients with respiratory distress syndrome&#xD;
&#xD;
          -  Patients with a history of bleeding disorders&#xD;
&#xD;
          -  Patients with bilirubin levels &gt; 2 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Eisenbrey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Eisenbrey, PhD</last_name>
    <phone>(215) 503-5188</phone>
    <email>john.eisenbrey@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Eisenbrey, MD</last_name>
      <email>john.eisenbrey@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org</url>
    <description>Sidney Kimmel Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

